Partners:
The STRUCTURE OF MANAGEMENT COUNCIL :
General Co-ordinator : Maya Simionescu
Research & Development Co-ordinator : Manuela Calin
Innovation Co-ordinator -Marius Enachescu
Ethical & Gender Issues : Aurelia Meghea
WP1 Leader: Management : Maya Simionescu
WP2 Leader: Design and characterization of targeted nanoparticles : Erdal Cevher
WP3 Leader: NP binding to activated EC : Manuela Calin
WP4 Leader: Detection of chemokine inhibitors release : Marius Enachescu
WP5 Leader: Assessment of therapeutic effects-in vitro studies : Gerd Bendas
WP6 Leader: Assessment of therapeutic effects , in vivo studies : Lubor Borsig
WP7 Leader: Cell sensor development : Teodor Necsoiu
WP8 Leader: Marketing strategy and dissemination : Reiner Zeissig
The work plan is comprising 8 work packages (WPs):
WP1: Scientific coordination, project management, knowledge management (all partners), 1-36 months
WP2: Design, preparation and characterization of different NP for targeted delivery of chemokine inhibitors (P1, P2, P4), months: 1-36
WP3: Assessment of targeted NP binding to the activated EC surface (P1, P3), months: 3-24
WP4: Detection of chemokine inhibitors (CA or CRA) release from different targeted NP to endothelial surface (P1, P2, P3, P4), months: 3-24
WP5: Assessment of the therapeutic effect of targeted NP-mediated CA or CRA (CA/CRA-NP) delivery to activated EC by detecting if they reduce cell adhesion and migration (P1, P3), months: 6-30
WP6: Assessment of the therapeutic effect of targeted NP-mediated CA or CRA (CA/CRA-NP) delivery – in vivo studies (P1, P6, P7), months: 3-36
WP7: Development of a diagnostic kit based on biosensor using nanoparticles (Cell Sensor) for detection of blood circulating inflammatory cells and tumour metastatic cells and implementation of an electronic prototype device for cells detection (P1, P2, P5, P6), months:1-36
WP 8. Marketing strategy and dissemination (all partners), months: 24-36